Regulation of TRAIL-receptor expression by the ubiquitin-proteasome system

International Journal of Molecular Sciences

Volumn 15, Issue 10, 2014, Pages 18557-18573

  Sarhan, Dhifaf ^a   D’Arcy, Padraig ^a   Lundqvist, Andreas ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

(TRAIL); Apoptosis; Cancer; Natural killer (NK) cells; T cells; TNF related apoptosis inducing lig; Ubiquitin proteasome system (UPS)

Indexed keywords

APOPTOTIC PEPTIDASE ACTIVATING FACTOR 1; CASPASE 10; CASPASE 3; CASPASE 6; CASPASE 7; CASPASE 8; CASPASE 9; CYTOCHROME C; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEIN; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DEUBIQUITINASE; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FAS LIGAND; FLICE INHIBITORY PROTEIN; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROCASPASE 8; PROTEASOME; PROTEASOME DEUBIQUITINASE INHIBITOR; PROTEIN BCL X; RECEPTOR INTERACTING PROTEIN; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED DEATH DOMAIN PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3; UBIQUITIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; TUMOR NECROSIS FACTOR;

APOPTOSIS; BREAST CARCINOMA; CANCER STAGING; CELL DEATH; CELL INFILTRATION; CELL PERMEABILIZATION; DRUG MECHANISM; ENZYME INHIBITION; GLIOBLASTOMA CELL LINE; HUMAN; NATURAL KILLER CELL; PANCREATIC CANCER CELL LINE; PHAGOCYTOSIS; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; REVIEW; ANIMAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS;

ANIMALS; APOPTOSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA; UBIQUITIN;

EID: 84907829595     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms151018557     Document Type: Review

References (102)

1. Jemal, A.; Bray, F.; Center, M. M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin. 2011, 61, 69-90.
2. Dasari, S.; Bernard Tchounwou, P. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur. J. Pharmacol. 2014, 740C, 364-378.
3. Watts, T. H. TNF/TNFR family members in costimulation of T cell responses. Ann. Rev. Immunol 2005, 23, 23-68.
4. 2 ligand. J. Clin. Investig. 1999, 104, 155-162.
5. Walczak, H.; Miller, R. E.; Ariail, K.; Gliniak, B.; Griffith, T. S.; Kubin, M.; Chin, W.; Jones, J.; Woodward, A.; Le, T.; et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 1999, 5, 157-163.
6. Nesterov, A.; Nikrad, M.; Johnson, T.; Kraft, A. S. Oncogenic Ras sensitizes normal human cells to tumor necrosis factor-α-related apoptosis-inducing ligand-induced apoptosis. Cancer Res. 2004, 64, 3922-3927.
7. Stuckey, D. W.; Shah, K. TRAIL on trial: Preclinical advances in cancer therapy. Trends Mol. Med. 2013, 19, 685-694.
8. Sarhan, D.; Wennerberg, E.; D'Arcy, P.; Gurajada, D.; Linder, S.; Lundqvist, A. A novel inhibitor of proteasome deubiquitinating activity renders tumor cells sensitive to TRAIL-mediated apoptosis by natural killer cells and T cells. Cancer Immunol. Immunother. 2013, 62, 1359-1368.
9. Dokouhaki, P.; Schuh, N. W.; Joe, B.; Allen, C. A.; Der, S. D.; Tsao, M. S.; Zhang, L. NKG2D regulates production of soluble TRAIL by ex vivo expanded human γδ T cells. Eur. J. Immunol. 2013, 43, 3175-3182.
10. Pan, G.; O'Rourke, K.; Chinnaiyan, A. M.; Gentz, R.; Ebner, R.; Ni, J.; Dixit, V. M. The receptor for the cytotoxic ligand TRAIL. Science 1997, 276, 111-113.
11. Schneider, P.; Olson, D.; Tardivel, A.; Browning, B.; Lugovskoy, A.; Gong, D.; Dobles, M.; Hertig, S.; Hofmann, K.; van Vlijmen, H.; et al. Identification of a new murine tumor necrosis factor receptor locus that contains two novel murine receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J. Biol. Chem. 2003, 278, 5444-5454.
12. Shirley, S.; Morizot, A.; Micheau, O. Regulating TRAIL receptor-induced cell death at the membrane: A deadly discussion. Recent Pat. Anti-Cancer Drug Dis. 2011, 6, 311-323.
13. 2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J. Biol. Chem. 2005, 280, 40599-40608.
14. Daniels, R. A.; Turley, H.; Kimberley, F. C.; Liu, X. S.; Mongkolsapaya, J.; Ch'En, P.; Xu, X. N.; Jin, B. Q.; Pezzella, F.; Screaton, G. R. Expression of TRAIL and TRAIL receptors in normal and malignant tissues. Cell Res. 2005, 15, 430-438.
15. Cretney, E.; Takeda, K.; Yagita, H.; Glaccum, M.; Peschon, J. J.; Smyth, M. J. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J. Immunol. 2002, 168, 1356-1361.
16. McCarthy, M. M.; DiVito, K. A.; Sznol, M.; Kovacs, D.; Halaban, R.; Berger, A. J.; Flaherty, K. T.; Camp, R. L.; Lazova, R.; Rimm, D. L.; et al. Expression of tumor necrosis factor-Related apoptosis-inducing ligand receptors 1 and 2 in melanoma. Clin. Cancer Res. 2006, 12, 3856-3863.
17. Perraud, A.; Akil, H.; Nouaille, M.; Petit, D.; Labrousse, F.; Jauberteau, M. O.; Mathonnet, M. Expression of p53 and DR5 in normal and malignant tissues of colorectal cancer: Correlation with advanced stages. Oncol. Rep. 2011, 26, 1091-1097.
18. Gallmeier, E.; Bader, D. C.; Kriegl, L.; Berezowska, S.; Seeliger, H.; Goke, B.; Kirchner, T.; Bruns, C.; de Toni, E. N. Loss of TRAIL-receptors is a recurrent feature in pancreatic cancer and determines the prognosis of patients with no nodal metastasis after surgery. PLoS One 2013, 8, e56760.
19. Sanlioglu, A. D.; Korcum, A. F.; Pestereli, E.; Erdogan, G.; Karaveli, S.; Savas, B.; Griffith, T. S.; Sanlioglu, S. TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma. Int J Radiat. Oncol. Biol. Phys. 2007, 69, 716-723.
20. Ruffin, N.; Ahmed, S. S.; Osorio, L. M.; Wang, X. N.; Jackson, G. H.; Collin, M. P.; Ekre, H. P.; Chiodi, F.; Dickinson, A. M. The involvement of epithelial Fas in a human model of graft versus host disease. Transplantation 2011, 91, 946-951.
21. Schungel, S.; Buitrago-Molina, L. E.; Nalapareddy, P.; Lebofsky, M.; Manns, M. P.; Jaeschke, H.; Gross, A.; Vogel, A. The strength of the Fas ligand signal determines whether hepatocytes act as type 1 or type 2 cells in murine livers. Hepatology 2009, 50, 1558-1566.
22. Wiley, S. R.; Schooley, K.; Smolak, P. J.; Din, W. S.; Huang, C. P.; Nicholl, J. K.; Sutherland, G. R.; Smith, T. D.; Rauch, C.; Smith, C. A.; et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995, 3, 673-682.
23. Holoch, P. A.; Griffith, T. S. TNF-related apoptosis-inducing ligand (TRAIL): A new path to anti-cancer therapies. Eur. J. Pharmacol. 2009, 625, 63-72.
24. Hughes, P. D.; Belz, G. T.; Fortner, K. A.; Budd, R. C.; Strasser, A.; Bouillet, P. Apoptosis regulators Fas and Bim cooperate in shutdown of chronic immune responses and prevention of autoimmunity. Immunity 2008, 28, 197-205.
25. + T cell contraction. Immunity 2008, 28, 218-230.
26. Bossi, G.; Griffiths, G. M. Degranulation plays an essential part in regulating cell surface expression of Fas ligand in T cells and natural killer cells. Nat. Med. 1999, 5, 90-96.
27. Kayagaki, N.; Kawasaki, A.; Ebata, T.; Ohmoto, H.; Ikeda, S.; Inoue, S.; Yoshino, K.; Okumura, K.; Yagita, H. Metalloproteinase-mediated release of human Fas ligand. J. Exp. Med. 1995, 182, 1777-1783.
28. Tanaka, M.; Itai, T.; Adachi, M.; Nagata, S. Down-regulation of Fas ligand by shedding. Nat. Med. 1998, 4, 31-36.
29. 2 ligand/trail expression in NK cells-involvement in NK cell-mediated cytotoxicity. Cytokine 1999, 11, 664-672.
30. Kayagaki, N.; Yamaguchi, N.; Nakayama, M.; Takeda, K.; Akiba, H.; Tsutsui, H.; Okamura, H.; Nakanishi, K.; Okumura, K.; Yagita, H. Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells. J. Immunol. 1999, 163, 1906-1913.
31. Sato, K.; Hida, S.; Takayanagi, H.; Yokochi, T.; Kayagaki, N.; Takeda, K.; Yagita, H.; Okumura, K.; Tanaka, N.; Taniguchi, T.; et al. Antiviral response by natural killer cells through TRAIL gene induction by IFN-α/β. Eur. J. Immunol. 2001, 31, 3138-3146.
32. Cummins, N.; Badley, A. The TRAIL to viral pathogenesis: The good, the bad and the ugly. Curr. Mol. Med. 2009, 9, 495-505.
33. Rethi, B.; Eidsmo, L. FasL and TRAIL signaling in the skin during cutaneous leishmaniasis-Implications for tissue immunopathology and infectious control. Front. Immunol. 2012, 3, 163.
34. Falschlehner, C.; Schaefer, U.; Walczak, H. Following TRAIL's path in the immune system. Immunology 2009, 127, 145-154.
35. Ueno, Y.; Ishii, M.; Yahagi, K.; Mano, Y.; Kisara, N.; Nakamura, N.; Shimosegawa, T.; Toyota, T.; Nagata, S. Fas-mediated cholangiopathy in the murine model of graft versus host disease. Hepatology 2000, 31, 966-974.
36. Sugimoto, M.; Shimaoka, M.; Hosotsubo, K.; Tanigami, H.; Taenaka, N.; Kiyono, H.; Yoshiya, I. Up-regulation of Fas ligand (FasL) mRNA expression in peripheral blood mononuclear cells (PBMC) after major surgery. Clin. Exp. Immunol. 1998, 112, 120-125.
37. Murata, J.; Abe, R.; Shimizu, H. Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment. J. Allergy Clin. Immunol. 2008, 122, 992-1000.
38. Viard, I.; Wehrli, P.; Bullani, R.; Schneider, P.; Holler, N.; Salomon, D.; Hunziker, T.; Saurat, J. H.; Tschopp, J.; French, L. E. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998, 282, 490-493.
39. Leu, J. I.; Crissey, M. A.; Taub, R. Massive hepatic apoptosis associated with TGF-β1 activation after Fas ligand treatment of IGF binding protein-1-deficient mice. J. Clin. Investig. 2003, 111, 129-139.
40. Sheard, M. A.; Asgharzadeh, S.; Liu, Y.; Lin, T. Y.; Wu, H. W.; Ji, L.; Groshen, S.; Lee, D. A.; Seeger, R. C. Membrane-bound TRAIL supplements natural killer cell cytotoxicity against neuroblastoma cells. J. Immunother. 2013, 36, 319-329.
41. Li, M.; Knight, D. A.; Smyth, M. J.; Stewart, T. J. Sensitivity of a novel model of mammary cancer stem cell-like cells to TNF-related death pathways. Cancer Immunol. Immunother. 2012, 61, 1255-1268.
42. Kajitani, K.; Tanaka, Y.; Arihiro, K.; Kataoka, T.; Ohdan, H. Mechanistic analysis of the antitumor efficacy of human natural killer cells against breast cancer cells. Breast Cancer Res. Treat. 2012, 134, 139-155.
43. Jazirehi, A. R.; Kurdistani, S. K.; Economou, J. S. Histone deacetylase inhibitor sensitizes apoptosis-resistant melanomas to cytotoxic human T lymphocytes through regulation of TRAIL/DR5 pathway. J. Immunol. 2014, 192, 3981-3989.
44. Ghosh, A.; Dogan, Y.; Moroz, M.; Holland, A. M.; Yim, N. L.; Rao, U. K.; Young, L. F.; Tannenbaum, D.; Masih, D.; Velardi, E.; et al. Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activity. J. Clin. Investig. 2013, 123, 2654-2662.
45. Walczak, H.; Haas, T. L. Biochemical analysis of the native TRAIL death-inducing signaling complex. Methods Mol. Biol. 2008, 414, 221-239.
46. Ashkenazi, A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat. Rev. Drug Discov. 2008, 7, 1001-1012.
47. Bodmer, J. L.; Holler, N.; Reynard, S.; Vinciguerra, P.; Schneider, P.; Juo, P.; Blenis, J.; Tschopp, J. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat. Cell Biol. 2000, 2, 241-243.
48. 2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000, 12, 611-620.
49. Budd, R. C.; Yeh, W. C.; Tschopp, J. cFLIP regulation of lymphocyte activation and development. Nat. Rev. Immunol. 2006, 6, 196-204.
50. Irmler, M.; Thome, M.; Hahne, M.; Schneider, P.; Hofmann, K.; Steiner, V.; Bodmer, J. L.; Schroter, M.; Burns, K.; Mattmann, C.; et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997, 388, 190-195.
51. Peter, M. E.; Krammer, P. H. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ. 2003, 10, 26-35.
52. Danial, N. N.; Korsmeyer, S. J. Cell death: Critical control points. Cell 2004, 116, 205-219.
53. Wei, M. C.; Zong, W. X.; Cheng, E. H.; Lindsten, T.; Panoutsakopoulou, V.; Ross, A. J.; Roth, K. A.; MacGregor, G. R.; Thompson, C. B.; Korsmeyer, S. J. Proapoptotic BAX and BAK: A requisite gateway to mitochondrial dysfunction and death. Science 2001, 292, 727-730.
54. Wang, P.; Zhang, J.; Bellail, A.; Jiang, W.; Hugh, J.; Kneteman, N. M.; Hao, C. Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells. Cell. Signal. 2007, 19, 2237-2246.
55. Wang, G.; Wang, X.; Yu, H.; Wei, S.; Williams, N.; Holmes, D. L.; Halfmann, R.; Naidoo, J.; Wang, L.; Li, L.; et al. Small-molecule activation of the TRAIL receptor DR5 in human cancer cells. Nat. Chem. Biol. 2013, 9, 84-89.
56. Wang, W.; Kim, S. H.; El-Deiry, W. S. Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts. Proc. Natl. Acad. Sci. USA 2006, 103, 11003-11008.
57. Wennerberg, E.; Sarhan, D.; Carlsten, M.; Kaminskyy, V. O.; D'Arcy, P.; Zhivotovsky, B.; Childs, R.; Lundqvist, A. Doxorubicin sensitizes human tumor cells to NK cell-and T-cell-mediated killing by augmented TRAIL receptor signaling. Int. J. Cancer 2013, 133, 1643-1652.
58. Vitovski, S.; Chantry, A. D.; Lawson, M. A.; Croucher, P. I. Targeting tumour-initiating cells with TRAIL based combination therapy ensures complete and lasting eradication of multiple myeloma tumours in vivo. PLoS One 2012, 7, e35830.
59. Borbone, E.; Berlingieri, M. T.; de Bellis, F.; Nebbioso, A.; Chiappetta, G.; Mai, A.; Altucci, L.; Fusco, A. Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation. Oncogene 2010, 29, 105-116.
60. Coca, S.; Perez-Piqueras, J.; Martinez, D.; Colmenarejo, A.; Saez, M. A.; Vallejo, C.; Martos, J. A.; Moreno, M. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 1997, 79, 2320-2328.
61. Ascierto, M. L.; Idowu, M. O.; Zhao, Y.; Khalak, H.; Payne, K. K.; Wang, X. Y.; Dumur, C. I.; Bedognetti, D.; Tomei, S.; Ascierto, P. A.; et al. Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients. J. Transl. Med. 2013, 11, 145.
62. Berg, M.; Lundqvist, A.; McCoy, P., Jr.; Samsel, L.; Fan, Y.; Tawab, A.; Childs, R. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 2009, 11, 341-355.
63. Sarhan, D.; Wennerberg, E.; Lundqvist, A. Unpublished work, 2014.
64. Sarhan, D.; D'Arcy, P.; Wennerberg, E.; Liden, M.; Hu, J.; Winqvist, O.; Rolny, C.; Lundqvist, A. Activated monocytes augment TRAIL-mediated cytotoxicity by human NK cells through release of IFN-γ. Eur. J. Immunol. 2013, 43, 249-257.
65. 2L/TRAIL) in patients with advanced tumours. Br. J. Cancer 2011, 105, 1830-1838.
66. Younes, A.; Vose, J. M.; Zelenetz, A. D.; Smith, M. R.; Burris, H. A.; Ansell, S. M.; Klein, J.; Halpern, W.; Miceli, R.; Kumm, E.; et al. A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma. Br. J. Cancer 2010, 103, 1783-1787.
67. Merchant, M. S.; Geller, J. I.; Baird, K.; Chou, A. J.; Galli, S.; Charles, A.; Amaoko, M.; Rhee, E. H.; Price, A.; Wexler, L. H.; et al. Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors. J. Clin. Oncol. 2012, 30, 4141-4147.
68. Zhang, X. D.; Nguyen, T.; Thomas, W. D.; Sanders, J. E.; Hersey, P. Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEBS Lett. 2000, 482, 193-199.
69. Zhang, Y.; Zhang, B. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. Mol. Cancer Res. 2008, 6, 1861-1871.
70. 2L/TRAIL. Nat. Med. 2007, 13, 1070-1077.
71. Ebinger, M.; Senf, L.; Wachowski, O.; Scheurlen, W. Promoter methylation pattern of caspase-8, P16INK4A, MGMT, TIMP-3, and E-cadherin in medulloblastoma. Pathol. Oncol. Res. 2004, 10, 17-21.
72. Hopkins-Donaldson, S.; Ziegler, A.; Kurtz, S.; Bigosch, C.; Kandioler, D.; Ludwig, C.; Zangemeister-Wittke, U.; Stahel, R. Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell. Death Differ. 2003, 10, 356-364.
73. Mitsiades, N.; Mitsiades, C. S.; Poulaki, V.; Anderson, K. C.; Treon, S. P. Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells. Blood 2002, 99, 2162-2171.
74. Zang, F.; Wei, X.; Leng, X.; Yu, M.; Sun, B. C-FLIP(L) contributes to TRAIL resistance in HER2-positive breast cancer. Biochem. Biophys. Res. Commun. 2014, 450, 267-273.
75. Ili, C. G.; Brebi, P.; Tapia, O.; Sandoval, A.; Lopez, J.; Garcia, P.; Leal, P.; Sidransky, D.; Guerrero-Preston, R.; Roa, J. C. Cellular FLICE-like inhibitory protein long form (c-FLIPL) overexpression is related to cervical cancer progression. Int. J. Gynecol. Pathol. 2013, 32, 316-322.
76. Seo, B. R.; Min, K. J.; Kim, S.; Park, J. W.; Park, W. K.; Lee, T. J.; Kwon, T. K. Anisomycin treatment enhances TRAIL-mediated apoptosis in renal carcinoma cells through the down-regulation of Bcl-2, c-FLIP(L) and Mcl-1. Biochimie 2013, 95, 858-865.
77. Sinicrope, F. A.; Penington, R. C.; Tang, X. M. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis is inhibited by Bcl-2 but restored by the small molecule Bcl-2 inhibitor, HA 14-1, in human colon cancer cells. Clin. Cancer Res. 2004, 10, 8284-8292.
78. Hinz, S.; Trauzold, A.; Boenicke, L.; Sandberg, C.; Beckmann, S.; Bayer, E.; Walczak, H.; Kalthoff, H.; Ungefroren, H. Bcl-XL protects pancreatic adenocarcinoma cells against CD95-and TRAIL-receptor-mediated apoptosis. Oncogene 2000, 19, 5477-5486.
79. Kulathu, Y.; Komander, D. Atypical ubiquitylation-The unexplored world of polyubiquitin beyond Lys48 and Lys63 linkages. Nat. Rev. Mol. Cell Biol. 2012, 13, 508-523.
80. Song, J. J.; Szczepanski, M. J.; Kim, S. Y.; Kim, J. H.; An, J. Y.; Kwon, Y. T.; Alcala, M. A., Jr.; Bartlett, D. L.; Lee, Y. J. c-Cbl-mediated degradation of TRAIL receptors is responsible for the development of the early phase of TRAIL resistance. Cell. Signal. 2010, 22, 553-563.
81. Van de Kooij, B.; Verbrugge, I.; de Vries, E.; Gijsen, M.; Montserrat, V.; Maas, C.; Neefjes, J.; Borst, J. Ubiquitination by the membrane-associated RING-CH-8 (MARCH-8) ligase controls steady-state cell surface expression of tumor necrosis factor-related apoptosis inducing ligand (TRAIL) receptor 1. J. Biol. Chem. 2013, 288, 6617-6628.
82. Jin, Z.; Li, Y.; Pitti, R.; Lawrence, D.; Pham, V. C.; Lill, J. R.; Ashkenazi, A. Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell 2009, 137, 721-735.
83. Bellail, A. C.; Olson, J. J.; Yang, X.; Chen, Z. J.; Hao, C. A20 ubiquitin ligase-mediated polyubiquitination of RIP1 inhibits caspase-8 cleavage and TRAIL-induced apoptosis in glioblastoma. Cancer Discov. 2012, 2, 140-155.
84. Li, Y.; Kong, Y.; Zhou, Z.; Chen, H.; Wang, Z.; Hsieh, Y. C.; Zhao, D.; Zhi, X.; Huang, J.; Zhang, J.; et al. The HECTD3 E3 ubiquitin ligase facilitates cancer cell survival by promoting K63-linked polyubiquitination of caspase-8. Cell Death Dis. 2013, 4, e935.
85. Christian, P. A.; Fiandalo, M. V.; Schwarze, S. R. Possible role of death receptor-mediated apoptosis by the E3 ubiquitin ligases Siah2 and POSH. Mol. Cancer 2011, 10, 57.
86. Zhou, Z.; Liu, R.; Chen, C. The WWP1 ubiquitin E3 ligase increases TRAIL resistance in breast cancer. Int. J. Cancer 2012, 130, 1504-1510.
87. Chang, L.; Kamata, H.; Solinas, G.; Luo, J. L.; Maeda, S.; Venuprasad, K.; Liu, Y. C.; Karin, M. The E3 ubiquitin ligase itch couples JNK activation to TNFα-induced cell death by inducing c-FLIP(L) turnover. Cell 2006, 124, 601-613.
88. De Wilt, L. H.; Kroon, J.; Jansen, G.; de Jong, S.; Peters, G. J.; Kruyt, F. A. Bortezomib and TRAIL: A perfect match for apoptotic elimination of tumour cells? Crit. Rev. Oncol./Hematol. 2013, 85, 363-372.
89. Liu, X.; Yue, P.; Chen, S.; Hu, L.; Lonial, S.; Khuri, F. R.; Sun, S. Y. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Cancer Res. 2007, 67, 4981-4988.
90. Kandasamy, K.; Kraft, A. S. Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region. Mol. Cancer Ther. 2008, 7, 1091-1100.
91. Chen, J. J.; Chou, C. W.; Chang, Y. F.; Chen, C. C. Proteasome inhibitors enhance TRAIL-induced apoptosis through the intronic regulation of DR5: Involvement of NF-κB and reactive oxygen species-mediated p53 activation. J. Immunol. 2008, 180, 8030-8039.
92. Lee, Y. J.; Seol, J. W.; Jeong, J. K.; Moon, M. H.; Park, S. Y. Inhibition of the ubiquitin-proteasome system sensitizes TRAIL-resistant prostate cancer cells by up-regulation of death receptor 5. Mol. Med. Rep. 2011, 4, 1255-1259.
93. Johnson, T. R.; Stone, K.; Nikrad, M.; Yeh, T.; Zong, W. X.; Thompson, C. B.; Nesterov, A.; Kraft, A. S. The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene 2003, 22, 4953-4963.
94. Hideshima, T.; Bradner, J. E.; Wong, J.; Chauhan, D.; Richardson, P.; Schreiber, S. L.; Anderson, K. C. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc. Natl. Acad. Sci. USA 2005, 102, 8567-8572.
95. Unterkircher, T.; Cristofanon, S.; Vellanki, S. H.; Nonnenmacher, L.; Karpel-Massler, G.; Wirtz, C. R.; Debatin, K. M.; Fulda, S. Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBID stability and mitochondrial apoptosis. Clin. Cancer Res. 2011, 17, 4019-4030.
96. Lundqvist, A.; Abrams, S. I.; Schrump, D. S.; Alvarez, G.; Suffredini, D.; Berg, M.; Childs, R. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: A novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res. 2006, 66, 7317-7325.
97. Lundqvist, A.; Berg, M.; Smith, A.; Childs, R. W. Bortezomib treatment to potentiate the anti-tumor immunity of ex-vivo expanded adoptively infused autologous natural killer cells. J. Cancer 2011, 2, 383-385.
98. D'Arcy, P.; Brnjic, S.; Olofsson, M. H.; Fryknas, M.; Lindsten, K.; de Cesare, M.; Perego, P.; Sadeghi, B.; Hassan, M.; Larsson, R.; et al. Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat. Med. 2011, 17, 1636-1640.
99. D'Arcy, P.; Linder, S. Proteasome deubiquitinases as novel targets for cancer therapy. Int. J. Biochem. Cell. Biol. 2012, 44, 1729-1738.
100. Zhao, L.; Yue, P.; Lonial, S.; Khuri, F. R.; Sun, S. Y. The NEDD8-activating enzyme inhibitor, MLN4924, cooperates with TRAIL to augment apoptosis through facilitating c-FLIP degradation in head and neck cancer cells. Mol. Cancer Ther. 2011, 10, 2415-2425.
101. Grund, K.; Ahmadi, R.; Jung, F.; Funke, V.; Gdynia, G.; Benner, A.; Sykora, J.; Walczak, H.; Joos, S.; Felsberg, J.; et al. Troglitazone-mediated sensitization to TRAIL-induced apoptosis is regulated by proteasome-dependent degradation of FLIP and ERK1/2-dependent phosphorylation of BAD. Cancer Biol. Ther. 2008, 7, 1982-1990.
102. Lundqvist, A.; Su, S.; Rao, S.; Childs, R. Cutting edge: Bortezomib-treated tumors sensitized to NK cell apoptosis paradoxically acquire resistance to antigen-specific T cells. J. Immunol. 2010, 184, 1139-1142.